The RAS/RAF/MEK/ERK signaling pathway is overexpressed or mutated in many malignant tumors, while MEK inhibitors can block tumor cell proliferation and induce cell death by inhibiting downstream signaling (47). This evidence concerns the gene MAP2K7 and cancer.